# ORal IrON Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension (ORION-PH-1)

> **NCT03371173** · PHASE3 · TERMINATED · sponsor: **Hannover Medical School** · enrollment: 22 (actual)

## Conditions studied

- Hypertension, Pulmonary
- Anemia, Iron Deficiency

## Interventions

- **DRUG:** Ferric maltol 30 mg (Feraccru®)

## Key facts

- **NCT ID:** NCT03371173
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-27
- **Primary completion:** 2020-03-19
- **Final completion:** 2020-03-19
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** low recruitment rate; difficulties to achieve planned number of participants within reasonable time frame
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03371173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03371173, "ORal IrON Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension (ORION-PH-1)". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT03371173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*